pharmaphorum10d
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and Merck & Co. The ...
News Medical1y
Tecentriq SC
Tecentriq solution for subcutaneous (SC ... cough, shortness of breath, rash, itchy skin and headache. The most common side effects when atezolizumab was given in combination with other anti ...
New Funding Of Treatment Will Help Many Of The Over 300 New Zealanders Diagnosed With Liver Cancer Each Year
New Zealanders now have funded access to a global standard of care treatment for a form of liver cancer, Hepatocellular Carcinoma (HCC), which, unlike many other cancers has a rapidly increasing rate ...
pharmaphorum3d
ASCO: TIGIT returns with Roche, Gilead data
although there were more instances of rash compared to the control group. Armed with the new data, Roche has decided to start a phase 3 trial comparing a tiragolumab, Tecentriq, and bevacizumab ...
Pharmabiz19d
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease
Chugai Pharmaceutical Co., Ltd. announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody ...